MedTrace Logo

Plantar Fasciitis, Operation or Conservative Treatment

NCT02448316 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-11

No results posted yet for this study

Summary

The purpose of this study is to compare in a randomized controlled trial the effect of endoscopic operation with the standard conservative treatmentprotocol with training supplemented with 1-3 injections of glucocorticoids in patients with chronic plantar fasciopathia.

Conditions

  • Plantar Fasciitis

Interventions

PROCEDURE

endoscopic surgery

Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus. A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion). Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,

DRUG

methylprednisolon

1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible

DRUG

lidokaine

1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible

BEHAVIORAL

Training

the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.

Sponsors & Collaborators

  • The Danish Rheumatism Association

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Finn MD Johannsen, MD · Institute of Sports Medicine Copenhagen, Bispebjerg Hospital Copenhagen, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2016-11-01
Completion
2017-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448316 on ClinicalTrials.gov